MX378726B - Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares. - Google Patents

Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.

Info

Publication number
MX378726B
MX378726B MX2018009061A MX2018009061A MX378726B MX 378726 B MX378726 B MX 378726B MX 2018009061 A MX2018009061 A MX 2018009061A MX 2018009061 A MX2018009061 A MX 2018009061A MX 378726 B MX378726 B MX 378726B
Authority
MX
Mexico
Prior art keywords
cancer
diseases
prevention
treatment
intracellular infections
Prior art date
Application number
MX2018009061A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Laboratories Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories Lc filed Critical Romark Laboratories Lc
Publication of MX378726B publication Critical patent/MX378726B/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F11/00—Rotary presses or machines having forme cylinders carrying a plurality of printing surfaces, or for performing letterpress, lithographic, or intaglio processes selectively or in combination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F13/00—Common details of rotary presses or machines
    • B41F13/08—Cylinders
    • B41F13/18—Impression cylinders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F13/00—Common details of rotary presses or machines
    • B41F13/08—Cylinders
    • B41F13/193—Transfer cylinders; Offset cylinders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/025—Multicolour printing or perfecting on sheets or on one or more webs, in one printing unit
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/04—Rotary lithographic machines for offset printing using printing units incorporating one forme cylinder, one transfer cylinder, and one impression cylinder, e.g. for printing on webs
    • B41F7/06—Rotary lithographic machines for offset printing using printing units incorporating one forme cylinder, one transfer cylinder, and one impression cylinder, e.g. for printing on webs for printing on sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/08—Rotary lithographic machines for offset printing using one transfer cylinder co-operating with several forme cylinders for printing on sheets or webs, e.g. sampling of colours on one transfer cylinder
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F9/00—Rotary intaglio printing presses
    • B41F9/02—Rotary intaglio printing presses for multicolour printing
    • B41F9/021—Sheet printing presses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona el uso de composiciones farmacéuticas que comprenden una tiazolida en la estimulación del sistema inmunitario un sujeto en necesidad de la misma, de este modo preservando y/o tratando enfermedades virales, cáncer y enfermedades causadas por infecciones protozoarias intracelulares.
MX2018009061A 2011-05-16 2012-05-15 Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares. MX378726B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486728P 2011-05-16 2011-05-16
PCT/US2012/037958 WO2012158699A1 (en) 2011-05-16 2012-05-15 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections

Publications (1)

Publication Number Publication Date
MX378726B true MX378726B (es) 2025-03-11

Family

ID=47175068

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009061A MX378726B (es) 2011-05-16 2012-05-15 Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
MX2013013115A MX2013013115A (es) 2011-05-16 2012-05-15 Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013013115A MX2013013115A (es) 2011-05-16 2012-05-15 Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.

Country Status (15)

Country Link
US (3) US20120294831A1 (es)
EP (1) EP2709453B1 (es)
JP (3) JP6138764B2 (es)
KR (1) KR102037162B1 (es)
CN (2) CN103648282B (es)
AU (1) AU2012255962B2 (es)
BR (1) BR112013029505A2 (es)
CA (1) CA2836253C (es)
DK (1) DK2709453T3 (es)
EA (1) EA024063B1 (es)
ES (1) ES2767304T3 (es)
IL (1) IL229459B (es)
MX (2) MX378726B (es)
WO (1) WO2012158699A1 (es)
ZA (1) ZA201308617B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102037162B1 (ko) * 2011-05-16 2019-10-29 로마크 레버러토리즈, 엘.씨. 바이러스병, 암 및 세포내 감염으로 인한 질병의 예방 및 치료를 위한 티아졸리드 화합물의 용도
KR20150139537A (ko) * 2013-03-15 2015-12-11 더 브로드 인스티튜트, 인코퍼레이티드 수지상 세포의 반응 유전자 발현, 물질의 조성물 및 이의 사용 방법
WO2015030504A1 (ko) * 2013-09-02 2015-03-05 가톨릭대학교 산학협력단 비소세포폐암 치료제를 유효성분으로 포함하는 톡소포자충감염증의 예방 또는 치료용 약학 조성물
KR101508611B1 (ko) 2013-09-02 2015-04-08 가톨릭대학교 산학협력단 아파티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
KR101508610B1 (ko) * 2013-09-02 2015-04-08 가톨릭대학교 산학협력단 다코미티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
EP3217795A4 (en) 2014-11-11 2018-08-22 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
US20180098972A1 (en) 2015-01-26 2018-04-12 Children's Medical Center Corporation Treatment of infectious diseases
MX381896B (es) 2016-03-31 2025-03-13 Romark Laboratories Lc Compuestos de tiazolida para el tratamiento de infecciones virales.
SG10202004425XA (en) 2016-04-11 2020-06-29 Genfit Methods of treatment for cholestatic and fibrotic diseases
CN105998036B (zh) * 2016-05-19 2018-07-27 洛阳市兽药厂 一种猪禽用复方磺胺硝唑尼特可溶性粉
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
CA3082859A1 (en) 2017-11-17 2019-05-23 Hubert Koster [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
BR112021020496A2 (pt) * 2019-04-12 2021-12-07 Genfit Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
TW202532387A (zh) 2019-07-26 2025-08-16 美商艾斯佩維他治療學公司 官能化的長鏈烴一元及二元羧酸及其用於預防或治療疾病的用途
CN113398125B (zh) 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
WO2022046622A1 (en) 2020-08-24 2022-03-03 Romark Laboratories L.C. Use of thiazolides against coronaviruses
CA3209453A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease
TW202245804A (zh) 2021-01-25 2022-12-01 美商艾斯佩維他治療學公司 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
WO2023077711A1 (zh) * 2021-11-03 2023-05-11 南方科技大学 预防前列腺癌的药剂的筛选方法及硝唑尼特在制药中的应用
CN114231611A (zh) * 2021-12-07 2022-03-25 中南大学湘雅二医院 干扰素诱导基因ifit3对b淋巴细胞活化及分化影响的研究方法
CN116539887A (zh) * 2023-01-09 2023-08-04 重庆医科大学 Psme1作为药物靶点在筛选或制备治疗乙型肝炎的药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5958038A (en) * 1997-11-07 1999-09-28 S3 Incorporated Computer processor with two addressable memories and two stream registers and method of data streaming of ALU operation
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
EP1871365A2 (en) 2005-04-12 2008-01-02 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
HUE065752T2 (hu) * 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
MX391013B (es) * 2009-06-26 2025-03-21 Romark Laboratories Lc Compuestos y metodos para tratar influenza.
US20110020272A1 (en) * 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
CN102666541B (zh) * 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
US20110223131A1 (en) * 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US9439878B2 (en) * 2010-06-03 2016-09-13 Douglas Tyler McKenzie Use of lumefantrine and related compounds in the treatment of cancer
JP2014510155A (ja) * 2011-04-06 2014-04-24 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス組み合わせ治療薬
KR102037162B1 (ko) * 2011-05-16 2019-10-29 로마크 레버러토리즈, 엘.씨. 바이러스병, 암 및 세포내 감염으로 인한 질병의 예방 및 치료를 위한 티아졸리드 화합물의 용도

Also Published As

Publication number Publication date
ZA201308617B (en) 2020-07-29
CN103648282A (zh) 2014-03-19
ES2767304T3 (es) 2020-06-17
CN103648282B (zh) 2017-02-15
US10336058B2 (en) 2019-07-02
US20120294831A1 (en) 2012-11-22
US20190291404A1 (en) 2019-09-26
KR20140028034A (ko) 2014-03-07
US20180126722A1 (en) 2018-05-10
EP2709453B1 (en) 2019-10-23
MX2013013115A (es) 2014-02-27
JP6138764B2 (ja) 2017-05-31
US10814612B2 (en) 2020-10-27
IL229459A0 (en) 2014-01-30
KR102037162B1 (ko) 2019-10-29
DK2709453T3 (da) 2020-01-20
IL229459B (en) 2021-05-31
BR112013029505A2 (pt) 2020-01-07
EP2709453A4 (en) 2014-11-19
CA2836253C (en) 2021-02-16
CA2836253A1 (en) 2012-11-22
EP2709453A1 (en) 2014-03-26
JP2019052175A (ja) 2019-04-04
JP2017149764A (ja) 2017-08-31
AU2012255962B2 (en) 2016-05-12
JP2014513725A (ja) 2014-06-05
WO2012158699A1 (en) 2012-11-22
EA024063B1 (ru) 2016-08-31
EA201391616A1 (ru) 2014-05-30
CN107096032A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX369803B (es) Derivados de acilaminopirimidina para el tratamiento de infecciones viricas y otras enfermedades.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
IN2013MU03118A (es)
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
BR112017019816A2 (pt) compostos, composição farmacêutica, método para o tratamento profilático ou terapêutico de doença dos rins e/ou fígado em um sujeito, e uso de um composto